title: In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant glioma.
abstract: The survival of patients with malignant gliomas is still unsatisfactory despite multimodality treatment, therefore new therapeutic strategies are required. Tumor necrosis factor apoptosis related ligand (TRAIL/Apo2L), a member of the tumor necrosis factor superfamily, may induce apoptotic cell death in several tumors, but not in normal cells, upon binding with specific receptors. In the present study, the expression and function of TRAIL receptors (TRAIL-R1/DR4 and TRAIL-R2/DR5) has been investigated in five human glioma cell lines (U87, U138, U373, A172, SW1783) in ex vivo tumors and in primary cultures obtained from the tumors. Our data show that gliomas preferentially express TRAIL R2 and that treatment with topotecan, a topoisomerase I inhibitor, significantly up-regulates its expression as detected by flow cytometry and western blotting. Moreover, in most cases, treatment with topotecan resulted in an increased sensitivity to TRAIL-dependent apoptosis, although cyclohexymide had to be added to induce apoptosis. On glioma cell lines, the effects of irradiation on TRAIL receptors were also analysed. In our experimental conditions, irradiation with 2 Gy had a modest additive effect on TRAIL-dependent apoptosis and was not able to modulate TRAIL receptor expression.
authors.affiliation: Department of Clinical Investigation, National Neurological Institute C. Besta, Via Celoria, Milan, Italy. eciusani@istituto-besta.it
authors.forename: Emilio
authors.initials: E
authors.lastname: Ciusani
authors.forename: Danilo
authors.initials: D
authors.lastname: Croci
authors.forename: Maurizio
authors.initials: M
authors.lastname: Gelati
authors.forename: Chiara
authors.initials: C
authors.lastname: Calatozzolo
authors.forename: Francesca
authors.initials: F
authors.lastname: Sciacca
authors.forename: Luisa
authors.initials: L
authors.lastname: Fumagalli
authors.forename: Marco
authors.initials: M
authors.lastname: Balzarotti
authors.forename: Laura
authors.initials: L
authors.lastname: Fariselli
authors.forename: Amerigo
authors.initials: A
authors.lastname: Boiardi
authors.forename: Andrea
authors.initials: A
authors.lastname: Salmaggi
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis; D051017:Apoptosis Regulatory Proteins; D045744:Cell Line, Tumor; D003131:Combined Modality Therapy; D005910:Glioma / Q000378:metabolism* / Q000628:therapy; D006801:Humans; D008562:Membrane Glycoproteins / Q000187:drug effects / Q000378:metabolism* / Q000528:radiation effects; D009423:Nervous System Neoplasms / Q000378:metabolism* / Q000628:therapy; D011839:Radiation, Ionizing; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D018124:Receptors, Tumor Necrosis Factor / Q000187:drug effects / Q000378:metabolism* / Q000528:radiation effects; D053221:TNF-Related Apoptosis-Inducing Ligand; D019772:Topotecan / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000187:drug effects / Q000378:metabolism* / Q000528:radiation effects
chemical_list: D000970:Antineoplastic Agents; D051017:Apoptosis Regulatory Proteins; D008562:Membrane Glycoproteins; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D018124:Receptors, Tumor Necrosis Factor; D053221:TNF-Related Apoptosis-Inducing Ligand; C105190:TNFRSF10A protein, human; C505639:TNFRSF10B protein, human; C505653:TNFSF10 protein, human; D014409:Tumor Necrosis Factor-alpha; D019772:Topotecan
references.citation: Nat Med. 2001 Apr;7(4):383-5
references.pmid: 11283636
references.citation: J Urol. 2001 Jan;165(1):263-70
references.pmid: 11125422
references.citation: J Neurooncol. 2002 Mar;57(1):27-36
references.pmid: 12125964
references.citation: Pharm World Sci. 1997 Jun;19(3):119-25
references.pmid: 9259027
references.citation: Nat Genet. 1997 Oct;17(2):141-3
references.pmid: 9326928
references.citation: Neuro Oncol. 2003 Jan;5(1):8-13
references.pmid: 12626128
references.citation: Cell. 1997 Feb 7;88(3):355-65
references.pmid: 9039262
references.citation: Oncology (Williston Park). 1998 Feb;12(2):233-40; discussion 240, 246
references.pmid: 9507524
references.citation: Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1754-9
references.pmid: 10677530
references.citation: Br J Cancer. 2003 Jan 27;88(2):298-306
references.pmid: 12610517
references.citation: Blood. 2001 May 1;97(9):2596-603
references.pmid: 11313247
references.citation: Hepatology. 2000 Sep;32(3):482-90
references.pmid: 10960439
references.citation: Biochem Pharmacol. 2002 Mar 1;63(5):881-7
references.pmid: 11911840
references.citation: Oncogene. 2001 Sep 13;20(41):5789-98
references.pmid: 11593384
references.citation: FEBS Lett. 2001 Sep 7;505(1):179-84
references.pmid: 11557065
references.citation: Nat Rev Cancer. 2002 Jun;2(6):420-30
references.pmid: 12189384
references.citation: Cancer Res. 2001 Feb 1;61(3):1162-70
references.pmid: 11221847
references.citation: Anticancer Res. 1997 Nov-Dec;17 (6B):4127-34
references.pmid: 9428346
references.citation: J Clin Invest. 1999 Jul;104(2):155-62
references.pmid: 10411544
references.citation: Immunol Today. 1992 May;13(5):151-3
references.pmid: 1322675
references.citation: Oncogene. 2001 Jul 12;20(31):4128-37
references.pmid: 11464279
references.citation: Scand J Immunol. 1995 May;41(5):504-8
references.pmid: 7725070
references.citation: Nat Med. 1999 Feb;5(2):157-63
references.pmid: 9930862
references.citation: Cancer Res. 1998 Apr 15;58(8):1593-8
references.pmid: 9563466
references.citation: Cancer Res. 2000 Feb 15;60(4):847-53
references.pmid: 10706092
references.citation: Oncogene. 2001 Apr 19;20(17):2190-6
references.pmid: 11360204
references.citation: Eur J Pharmacol. 2001 Jan 19;412(1):21-5
references.pmid: 11166732
references.citation: Cancer Res. 2000 Oct 15;60(20):5754-60
references.pmid: 11059770